Developer docs
API playgroundTry for free, no card

Search company profiles

Synexa Life Sciences

Full company profile

uuid0006g7b

Namestring
Synexa Life Sciences
Legal namestring
Synexa Group
Websiteurl
synexagroup.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex, custom-designed assays for pharmaceutical and biotechnology clients from discovery through regulatory submission. Its service portfolio spans soluble biomarker analysis (custom panels run on MSD, LC-MS/MS, ELISA, RIA, Olink PEA), regulated bioanalysis (PK, TK, PD, and immunogenicity), mass spectrometry-based quantification of small molecules, peptides, proteins, and ADCs, ligand-binding immunoassays, Gyrolab automated nano-scale immunoassays, high-parameter flow cytometry validated to CLSI H62, ELISpot and Fluorospot, GMP/GLP-accredited radiopharmaceutical bioanalysis, GCLP-accredited genomics (qPCR, ddPCR, sequencing, ctDNA), and spatial biology/tissue imaging. The platform is delivered from three GxP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), with a 16,500 sq ft dedicated mass spectrometry facility in Manchester and a radiopharmaceutical-licensed facility in Turku that has held its licence for 15+ years.\n\nThe company monetises its capability stack through project-based CRO contracts, with pricing set bespoke per study based on assay complexity, sample volume, regulatory tier (GLP/GCP/GCLP/GMP/ICH M10), platforms employed, and study duration. Sales are direct and enterprise-led, structured as multi-phase engagements spanning preclinical work through Phase III, with no public rate card. Customer segments are primarily large pharmaceutical companies and biotechnology firms developing complex modalities (ADCs, cell therapies, gene therapies, biosimilars, radiopharmaceuticals, vaccines), with named public references concentrated in mid-sized biotechs. Synexa has 150+ validated biomarker assays, what it describes as the highest number of reportable flow cytometry parameters in a single study, and 120+ scientists (60% of a 200+ total headcount).\n\nSynexa is privately held and is part of the Synexa Group corporate structure, registered in the Netherlands with wholly-owned operating subsidiaries in the UK (Synexa Life Sciences Ltd.), Finland (Synexa Life Sciences Finland OY), and South Africa (Synexa Life Sciences (Pty) Ltd.). Ownership is anchored by Gilde Healthcare, a European healthcare-focused private equity firm that has backed a stated "buy-and-build" expansion strategy executed through two acquisitions: Syrinx Bioanalytics in May 2022 (establishing the Finnish radiopharmaceutical platform) and Alderley Analytical Ltd. in October 2024 (adding UK LC-MS/MS and ligand-binding scale, along with Alderley co-founder Sally Hannam, now Scientific Director). Most recently, the company secured Gyrolab CRO certification and an early-adopter partnership with Waters Corporation for the Xevo TQ Absolute XR mass spectrometer in June 2025, alongside a My Green Lab certification at the Cape Town site. Revenue is not publicly disclosed.

Short descriptiontext

Synexa Life Sciences is a specialist biomarker and bioanalytical CRO with 200+ staff and 120+ scientists across three GxP-accredited laboratories in Manchester, Turku, and Cape Town, serving pharmaceutical and biotech clients from discovery through regulatory submission with assays spanning mass spectrometry, immunoassays, flow cytometry, genomics, and radiopharmaceuticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker analysis services, bioanalytical testing, clinical trial bioanalysis, mass spectrometry services, immunoassay development
Industry3 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Bioanalytical Contract Research Organization (CRO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

Synexa operates as a biomarker and bioanalytical CRO providing project-based contract research services to pharmaceutical and biotech companies. Services are tailored to each client's clinical development programme, spanning discovery through regulatory submission. Revenue is generated through fee-for-service project contracts, typically structured as multi-phase engagements from preclinical through Phase III clinical studies.

synexagroup.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based CRO service pricing - bespoke quotes for biomarker and bioanalytical projects
ModelOtherBilling cadenceMulti-year contract
Notes

Custom project pricing based on assay complexity, number of samples, regulatory requirements (GLP/GCP), number of technology platforms employed, and study duration. Contact-based engagement for consultation and project scoping. No public pricing tiers available.

synexagroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex custom-designed assays for pharmaceutical and biotech clients. Operating three GLP/GCP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), the company supports drug development programs from discovery through regulatory submission with services spanning mass spectrometry, immunoassays, proteomics, flow cytometry, genomics, tissue imaging, and radiopharmaceutical bioanalysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Highest number of reportable flow cytometry parameters in one study
+2 more records
Product overview1 text field

Synexa Life Sciences is a biomarker and bioanalytical Contract Research Organization (CRO) providing specialist laboratory services across the drug development pipeline. The company operates a platform of integrated services organized around core technology areas: Translational Science (human disease model validation), Soluble Biomarkers (custom panels using MSD, LC-MS/MS, ELISA platforms), Regulated Bioanalysis (GLP/GCP-compliant PK/PD/immunogenicity), Mass Spectrometry (LC-MS/MS), Immunoassay Services (ligand-binding assays), Olink Proteomics (proximity extension assay), Flow Cytometry (CLSI H62-validated), ELISpot/FluoroSpot, Radiopharmaceutical Bioanalysis (GMP/GLP), Genomics (GCLP qPCR/dPCR/sequencing), Tissue Imaging (spatial biology), and Dose Formulation Analysis. The company also offers specialized expertise in Autoimmune, Oncology, Vaccines, Biosimilars, ADCs, and Cell Therapies. With over 200 staff across three global laboratory locations in Manchester (UK), Turku (Finland), and Cape Town (South Africa), Synexa delivers complex, custom-designed assays supporting customers from discovery through regulatory submission. Recent acquisitions of Alderley Analytical (2024) and Syrinx Bioanalytics (2022) have expanded large-molecule bioanalysis capabilities.

Product and service14 records
1Translational Science Services
CategoryTranslational Science / Biomarker Services
Description

Human disease model validation services that generate mechanistic data from fresh patient samples to predict clinical response, guide biomarker strategy, and strengthen regulatory submissions before clinical entry. Aimed at pharmaceutical and biotech companies developing novel therapeutics.

2Soluble Biomarker Solutions
CategoryBiomarker Analysis Services
Description

Custom biomarker panel development and measurement services for target engagement, pathway modulation, disease activity, and clinical signals from Phase I through approval, using MSD, LC-MS/MS, ELISA, RIA, fluorescence, and luminescence-based technologies. Serves pharmaceutical and biotech R&D teams.

3Regulated Bioanalysis
CategoryRegulated Bioanalytical Services
Description

Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints, leveraging over 20 years of expertise in LC-MS/MS, MSD, and immunoassay platforms with GLP/GCP compliance for regulatory submissions. For pharma and biotech clients developing small and large molecule therapeutics.

4Mass Spectrometry Services
CategoryMass Spectrometry Bioanalysis
Description

LC-MS/MS quantification services for small molecules, peptides, proteins, and ADCs from a dedicated 16,500 sq ft UK facility, delivering ICH M10-validated PK, TK, and biomarker analysis with GLP/GCP compliance. Serves pharmaceutical, biotech, and biosimilar developers.

5Immunoassay Services
CategoryImmunoassay / Ligand-Binding Assay Services
Description

Ligand-binding assay design and validation for PK, ADA, and biomarker quantification, delivering precision and GCP/GLP compliance for regulatory decision-making. Used by pharma and biotech clients across clinical development phases.

6Olink Proteomics Services
CategoryProteomics Services
Description

Protein biomarker signature discovery using Olink's Proximity Extension Assay technology, analyzing up to 92 proteins from 1 µL with high sensitivity and specificity for biomarker discovery, patient stratification, and mechanism-of-action studies. For pharma and biotech researchers.

7Flow Cytometry Services
CategoryFlow Cytometry Services
Description

High-parameter flow cytometry analysis validated to CLSI H62 standards for immunophenotyping rare cells, measuring target engagement, and immune function with custom panels tailored to client endpoints. For cell therapy, immuno-oncology, and vaccine developers.

8ELISpot Assay Services
CategoryELISpot / Immune Monitoring Services
Description

GCLP-compliant ELISpot assays for detecting low-frequency T-cell and B-cell responses critical for vaccine development, immunotherapy monitoring, and CAR-T assessment with sensitive cytokine detection. Used by vaccine developers, immunotherapists, and cell therapy sponsors.

9Radiopharmaceutical Bioanalysis
CategoryRadiopharmaceutical Bioanalysis
Description

GMP/GLP-accredited bioanalysis at the Turku facility handling Ac-225, Th-227, I-131, and other radioisotopes, with radioactive sample management, PK analysis, and immunogenicity testing; licensed for 15+ years. For radiopharmaceutical developers.

10Genomics Services
CategoryGenomics Services
Description

GCLP-accredited genomics services including SNP detection, qPCR, ddPCR, targeted sequencing, and ctDNA quantification, supporting cell therapy bioanalysis, viral shedding studies, and pharmacogenomics. Serves cell/gene therapy and pharmacogenomics programs.

11Tissue Imaging Services
CategoryTissue Imaging / Spatial Biology
Description

Spatial biology services including multiplex immunofluorescence, super-resolution microscopy, and correlative light and electron microscopy (CLEM) to reveal cellular organisation, target engagement, and off-target effects from drug candidate selection through mechanism-of-action studies. For pharma and biotech discovery/translational teams.

12Dose Formulation Analysis
CategoryDose Formulation Analysis
Description

GLP toxicology study support verifying formulation accuracy, concentration consistency, and shelf-life at the Manchester facility using validated analytical methods. Supports preclinical toxicology and GLP study sponsors.

13ADC Bioanalysis Solutions
CategoryADC Bioanalysis
Description

Comprehensive bioanalytical solutions for antibody-drug conjugate programmes covering pharmacokinetics (intact ADC, total antibody, free payload), immunogenicity profiling, mechanisms of resistance, and safety evaluation. For ADC developers.

14Cell Therapy Bioanalysis
CategoryCell Therapy Bioanalysis
Description

Integrated biomarker and bioanalytical solutions for cell therapy development (CAR-T and NK cell therapies) including translational science, immune monitoring, flow cytometry, proteomics, GCLP genomics, and immunogenicity assessment, with persistence monitoring via qPCR/dPCR and viral shedding studies. For cell and gene therapy developers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-11
Description

Long-standing partnership with Gyros Protein Technologies for Gyrolab automated nanolitre-scale immunoassay platform. Synexa achieved official Gyrolab CRO certification in June 2025 after working closely with Gyros to validate and optimise workflows meeting highest industry standards. Partnership driven by shared commitment to innovation and excellence.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-10
Description

Technology partnership with Waters Corporation as one of the first bioanalytical laboratories to trial the new Xevo TQ Absolute XR Mass Spectrometer at Synexa's Manchester site. The collaboration evaluated hardware and software performance across complex assays including metal chelators and oligonucleotides, with Waters Connect software enhancing data processing efficiency and regulatory compliance.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-05-19
Description

Synexa acquired Finnish CRO Syrinx Bioanalytics in May 2022 to expand bioanalysis capabilities. The acquisition enhanced Synexa's service offerings, scientific expertise, and global footprint, supporting drug development in the pharma, biotech, and biosimilar sectors.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-headquartered bioanalytical CRO specialising in large-molecule bioanalysis, immunogenicity, PK/PD, and biomarker services for pharma and biotech — directly comparable to Synexa's core offering across similar technology platforms and customer segments.

TypeDirect peer
Description

Early-stage clinical bioanalytical CRO providing LC-MS/MS, ligand-binding assays, and biomarker services to pharma/biotech — overlaps heavily with Synexa's regulated bioanalysis and translational science offerings.

TypeDirect peer
Description

Global CRO/CDMO offering integrated bioanalytical services including LC-MS/MS, immunoassay, and biomarker analysis for drug development — competes with Synexa in regulated bioanalysis and large-molecule support.

TypeBroad incumbent
Description

Part of Eurofins Scientific's global network, offering bioanalytical, biomarker, and immunogenicity services at larger scale across multiple continents — broader portfolio than Synexa but overlapping core bioanalytical capabilities.

TypeBroad incumbent
Description

Global CRO with established bioanalytical, biomarker, and immunogenicity service lines serving pharma/biotech — offers Synexa's capabilities as part of a much larger discovery-through-manufacturing portfolio.

TypeBroad incumbent
Description

Large clinical CRO with bioanalytical laboratories supporting PK/PD, immunogenicity, and biomarker analysis — overlaps with Synexa's regulated bioanalysis but operates at significantly greater scale across full clinical development.

TypeBroad incumbent
Description

Largest global CRO with bioanalytical and biomarker capabilities embedded in a full-service clinical development offering — competes with Synexa for biomarker and bioanalytical contracts as part of broader enterprise deals.

TypeBroad incumbent
Description

Global CRO with bioanalytical and laboratory services for clinical trials, including biomarker and PK/PD support — overlaps with Synexa's regulated bioanalysis offerings within a much wider portfolio.

TypeRegional player
Description

Global testing services network with bioanalytical and clinical trial laboratory services — comparable service mix to Synexa but operates across a broader geographic footprint with more diversified end markets.

TypeBroad incumbent
Description

Global CRO/CDMO providing bioanalytical, biomarker, and laboratory services across discovery through manufacturing — directly comparable capabilities to Synexa but at much larger scale and broader service portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synexa Life Sciences

Bioanalytical Contract Research Organization (CRO)synexagroup.com

Synexa Life Sciences is a specialist biomarker and bioanalytical CRO with 200+ staff and 120+ scientists across three GxP-accredited laboratories in Manchester, Turku, and Cape Town, serving pharmaceutical and biotech clients from discovery through regulatory submission with assays spanning mass spectrometry, immunoassays, flow cytometry, genomics, and radiopharmaceuticals.

What Synexa Life Sciences does

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex, custom-designed assays for pharmaceutical and biotechnology clients from discovery through regulatory submission. Its service portfolio spans soluble biomarker analysis (custom panels run on MSD, LC-MS/MS, ELISA, RIA, Olink PEA), regulated bioanalysis (PK, TK, PD, and immunogenicity), mass spectrometry-based quantification of small molecules, peptides, proteins, and ADCs, ligand-binding immunoassays, Gyrolab automated nano-scale immunoassays, high-parameter flow cytometry validated to CLSI H62, ELISpot and Fluorospot, GMP/GLP-accredited radiopharmaceutical bioanalysis, GCLP-accredited genomics (qPCR, ddPCR, sequencing, ctDNA), and spatial biology/tissue imaging. The platform is delivered from three GxP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), with a 16,500 sq ft dedicated mass spectrometry facility in Manchester and a radiopharmaceutical-licensed facility in Turku that has held its licence for 15+ years.\n\nThe company monetises its capability stack through project-based CRO contracts, with pricing set bespoke per study based on assay complexity, sample volume, regulatory tier (GLP/GCP/GCLP/GMP/ICH M10), platforms employed, and study duration. Sales are direct and enterprise-led, structured as multi-phase engagements spanning preclinical work through Phase III, with no public rate card. Customer segments are primarily large pharmaceutical companies and biotechnology firms developing complex modalities (ADCs, cell therapies, gene therapies, biosimilars, radiopharmaceuticals, vaccines), with named public references concentrated in mid-sized biotechs. Synexa has 150+ validated biomarker assays, what it describes as the highest number of reportable flow cytometry parameters in a single study, and 120+ scientists (60% of a 200+ total headcount).\n\nSynexa is privately held and is part of the Synexa Group corporate structure, registered in the Netherlands with wholly-owned operating subsidiaries in the UK (Synexa Life Sciences Ltd.), Finland (Synexa Life Sciences Finland OY), and South Africa (Synexa Life Sciences (Pty) Ltd.). Ownership is anchored by Gilde Healthcare, a European healthcare-focused private equity firm that has backed a stated "buy-and-build" expansion strategy executed through two acquisitions: Syrinx Bioanalytics in May 2022 (establishing the Finnish radiopharmaceutical platform) and Alderley Analytical Ltd. in October 2024 (adding UK LC-MS/MS and ligand-binding scale, along with Alderley co-founder Sally Hannam, now Scientific Director). Most recently, the company secured Gyrolab CRO certification and an early-adopter partnership with Waters Corporation for the Xevo TQ Absolute XR mass spectrometer in June 2025, alongside a My Green Lab certification at the Cape Town site. Revenue is not publicly disclosed.

Synexa Life Sciences firmographics

Firmographics
Name
Synexa Life Sciences
Legal name
Synexa Group
Website
https://synexagroup.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Synexa Life Sciences is a specialist biomarker and bioanalytical CRO with 200+ staff and 120+ scientists across three GxP-accredited laboratories in Manchester, Turku, and Cape Town, serving pharmaceutical and biotech clients from discovery through regulatory submission with assays spanning mass spectrometry, immunoassays, flow cytometry, genomics, and radiopharmaceuticals.
Ownership category
akta.pro rank

Synexa Life Sciences industry classification

Industry
Product category
Bioanalytical Contract Research Organization (CRO)
NAICS
Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Biomarker analysis services
  • Bioanalytical testing
  • Clinical trial bioanalysis
  • Mass spectrometry services
  • Immunoassay development

Where Synexa Life Sciences is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Synexa Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Synexa operates as a biomarker and bioanalytical CRO providing project-based contract research services to pharmaceutical and biotech companies. Services are tailored to each client's clinical development programme, spanning discovery through regulatory submission. Revenue is generated through fee-for-service project contracts, typically structured as multi-phase engagements from preclinical through Phase III clinical studies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CRO service pricing - bespoke quotes for biomarker and bioanalytical projects

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Synexa Life Sciences product offering

Product offering

Core offering

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex custom-designed assays for pharmaceutical and biotech clients. Operating three GLP/GCP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), the company supports drug development programs from discovery through regulatory submission with services spanning mass spectrometry, immunoassays, proteomics, flow cytometry, genomics, tissue imaging, and radiopharmaceutical bioanalysis.

Product overview

Synexa Life Sciences is a biomarker and bioanalytical Contract Research Organization (CRO) providing specialist laboratory services across the drug development pipeline. The company operates a platform of integrated services organized around core technology areas: Translational Science (human disease model validation), Soluble Biomarkers (custom panels using MSD, LC-MS/MS, ELISA platforms), Regulated Bioanalysis (GLP/GCP-compliant PK/PD/immunogenicity), Mass Spectrometry (LC-MS/MS), Immunoassay Services (ligand-binding assays), Olink Proteomics (proximity extension assay), Flow Cytometry (CLSI H62-validated), ELISpot/FluoroSpot, Radiopharmaceutical Bioanalysis (GMP/GLP), Genomics (GCLP qPCR/dPCR/sequencing), Tissue Imaging (spatial biology), and Dose Formulation Analysis. The company also offers specialized expertise in Autoimmune, Oncology, Vaccines, Biosimilars, ADCs, and Cell Therapies. With over 200 staff across three global laboratory locations in Manchester (UK), Turku (Finland), and Cape Town (South Africa), Synexa delivers complex, custom-designed assays supporting customers from discovery through regulatory submission. Recent acquisitions of Alderley Analytical (2024) and Syrinx Bioanalytics (2022) have expanded large-molecule bioanalysis capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Translational Science Services Human disease model validation services that generate mechanistic data from fresh patient samples to predict clinical response, guide biomarker strategy, and strengthen regulatory submissions before clinical entry. Aimed at pharmaceutical and biotech companies developing novel therapeutics.
  • Soluble Biomarker Solutions Custom biomarker panel development and measurement services for target engagement, pathway modulation, disease activity, and clinical signals from Phase I through approval, using MSD, LC-MS/MS, ELISA, RIA, fluorescence, and luminescence-based technologies. Serves pharmaceutical and biotech R&D teams.
  • Regulated Bioanalysis Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints, leveraging over 20 years of expertise in LC-MS/MS, MSD, and immunoassay platforms with GLP/GCP compliance for regulatory submissions. For pharma and biotech clients developing small and large molecule therapeutics.
  • Mass Spectrometry Services LC-MS/MS quantification services for small molecules, peptides, proteins, and ADCs from a dedicated 16,500 sq ft UK facility, delivering ICH M10-validated PK, TK, and biomarker analysis with GLP/GCP compliance. Serves pharmaceutical, biotech, and biosimilar developers.
  • Immunoassay Services Ligand-binding assay design and validation for PK, ADA, and biomarker quantification, delivering precision and GCP/GLP compliance for regulatory decision-making. Used by pharma and biotech clients across clinical development phases.
  • Olink Proteomics Services Protein biomarker signature discovery using Olink's Proximity Extension Assay technology, analyzing up to 92 proteins from 1 µL with high sensitivity and specificity for biomarker discovery, patient stratification, and mechanism-of-action studies. For pharma and biotech researchers.
  • Flow Cytometry Services High-parameter flow cytometry analysis validated to CLSI H62 standards for immunophenotyping rare cells, measuring target engagement, and immune function with custom panels tailored to client endpoints. For cell therapy, immuno-oncology, and vaccine developers.
  • ELISpot Assay Services GCLP-compliant ELISpot assays for detecting low-frequency T-cell and B-cell responses critical for vaccine development, immunotherapy monitoring, and CAR-T assessment with sensitive cytokine detection. Used by vaccine developers, immunotherapists, and cell therapy sponsors.
  • Radiopharmaceutical Bioanalysis GMP/GLP-accredited bioanalysis at the Turku facility handling Ac-225, Th-227, I-131, and other radioisotopes, with radioactive sample management, PK analysis, and immunogenicity testing; licensed for 15+ years. For radiopharmaceutical developers.
  • Genomics Services GCLP-accredited genomics services including SNP detection, qPCR, ddPCR, targeted sequencing, and ctDNA quantification, supporting cell therapy bioanalysis, viral shedding studies, and pharmacogenomics. Serves cell/gene therapy and pharmacogenomics programs.
  • Tissue Imaging Services Spatial biology services including multiplex immunofluorescence, super-resolution microscopy, and correlative light and electron microscopy (CLEM) to reveal cellular organisation, target engagement, and off-target effects from drug candidate selection through mechanism-of-action studies. For pharma and biotech discovery/translational teams.
  • Dose Formulation Analysis GLP toxicology study support verifying formulation accuracy, concentration consistency, and shelf-life at the Manchester facility using validated analytical methods. Supports preclinical toxicology and GLP study sponsors.
  • ADC Bioanalysis Solutions Comprehensive bioanalytical solutions for antibody-drug conjugate programmes covering pharmacokinetics (intact ADC, total antibody, free payload), immunogenicity profiling, mechanisms of resistance, and safety evaluation. For ADC developers.
  • Cell Therapy Bioanalysis Integrated biomarker and bioanalytical solutions for cell therapy development (CAR-T and NK cell therapies) including translational science, immune monitoring, flow cytometry, proteomics, GCLP genomics, and immunogenicity assessment, with persistence monitoring via qPCR/dPCR and viral shedding studies. For cell and gene therapy developers.

Quantifiable outcome

  • Highest number of reportable flow cytometry parameters in one study
  • +2 more outcomes

Companies that use Synexa Life Sciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Synexa Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Synexa Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Gyros Protein TechnologiescoreTechnology or Integration · 11 June 2025Long-standing partnership with Gyros Protein Technologies for Gyrolab automated nanolitre-scale immunoassay platform. Synexa achieved official Gyrolab CRO certification in June 2025 after working closely with Gyros to validate and optimise workflows meeting highest industry standards. Partnership driven by shared commitment to innovation and excellence.
  • Waters CorporationcoreTechnology or Integration · 10 June 2025Technology partnership with Waters Corporation as one of the first bioanalytical laboratories to trial the new Xevo TQ Absolute XR Mass Spectrometer at Synexa's Manchester site. The collaboration evaluated hardware and software performance across complex assays including metal chelators and oligonucleotides, with Waters Connect software enhancing data processing efficiency and regulatory compliance.
  • Syrinx BioanalyticsminorStrategic or Co-development Partner · 19 May 2022Synexa acquired Finnish CRO Syrinx Bioanalytics in May 2022 to expand bioanalysis capabilities. The acquisition enhanced Synexa's service offerings, scientific expertise, and global footprint, supporting drug development in the pharma, biotech, and biosimilar sectors.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Synexa Life Sciences competitors and assessment

Company assessment

Direct peers

  • BioAgilytix Labs: US-headquartered bioanalytical CRO specialising in large-molecule bioanalysis, immunogenicity, PK/PD, and biomarker services for pharma and biotech — directly comparable to Synexa's core offering across similar technology platforms and customer segments.
  • Celerion: Early-stage clinical bioanalytical CRO providing LC-MS/MS, ligand-binding assays, and biomarker services to pharma/biotech — overlaps heavily with Synexa's regulated bioanalysis and translational science offerings.
  • Pharmaron: Global CRO/CDMO offering integrated bioanalytical services including LC-MS/MS, immunoassay, and biomarker analysis for drug development — competes with Synexa in regulated bioanalysis and large-molecule support.

Broad incumbents

  • Eurofins Bioanalytical Services: Part of Eurofins Scientific's global network, offering bioanalytical, biomarker, and immunogenicity services at larger scale across multiple continents — broader portfolio than Synexa but overlapping core bioanalytical capabilities.
  • Charles River Laboratories: Global CRO with established bioanalytical, biomarker, and immunogenicity service lines serving pharma/biotech — offers Synexa's capabilities as part of a much larger discovery-through-manufacturing portfolio.
  • Labcorp Drug Development (Fortrea): Large clinical CRO with bioanalytical laboratories supporting PK/PD, immunogenicity, and biomarker analysis — overlaps with Synexa's regulated bioanalysis but operates at significantly greater scale across full clinical development.
  • IQVIA: Largest global CRO with bioanalytical and biomarker capabilities embedded in a full-service clinical development offering — competes with Synexa for biomarker and bioanalytical contracts as part of broader enterprise deals.
  • ICON plc: Global CRO with bioanalytical and laboratory services for clinical trials, including biomarker and PK/PD support — overlaps with Synexa's regulated bioanalysis offerings within a much wider portfolio.
  • WuXi AppTec: Global CRO/CDMO providing bioanalytical, biomarker, and laboratory services across discovery through manufacturing — directly comparable capabilities to Synexa but at much larger scale and broader service portfolio.

Regional players

  • SGS Health Sciences: Global testing services network with bioanalytical and clinical trial laboratory services — comparable service mix to Synexa but operates across a broader geographic footprint with more diversified end markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Synexa Life Sciences social profiles

Digital presence

Synexa Life Sciences compliance and trust

Trust signal

Compliance7 records

Synexa Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synexa Life Sciences leadership team

Management profile

Number of profiles

Profiles6 records

Synexa Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Synexa Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synexa Life Sciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synexa Life Sciences

What does Synexa Life Sciences do?

Synexa Life Sciences is a specialist biomarker and bioanalytical contract research organization (CRO) that develops, validates, and delivers complex custom-designed assays for pharmaceutical and biotech clients. Operating three GLP/GCP-accredited laboratories in Manchester (UK), Turku (Finland), and Cape Town (South Africa), the company supports drug development programs from discovery through regulatory submission with services spanning mass spectrometry, immunoassays, proteomics, flow cytometry, genomics, tissue imaging, and radiopharmaceutical bioanalysis.

Is Synexa Life Sciences a public or private company?

Synexa Life Sciences is a private company. It is classified as private equity controlled and is currently operating.

When was Synexa Life Sciences founded?

Synexa Life Sciences was founded in 2004. It employs 101 to 250 people.

Where is Synexa Life Sciences based?

Synexa Life Sciences is headquartered in Manchester, United Kingdom, in the Europe region.

How does Synexa Life Sciences make money?

One revenue line is on record: contract Research Services (CRO).

Who are Synexa Life Sciences's main competitors?

Direct peers on record are BioAgilytix Labs, Celerion and Pharmaron. Broad incumbents are Eurofins Bioanalytical Services, Charles River Laboratories, Labcorp Drug Development (Fortrea), IQVIA, ICON plc and WuXi AppTec. SGS Health Sciences is listed as a regional player.

Does Synexa Life Sciences have an API?

No public API is recorded for Synexa Life Sciences.

What industry is Synexa Life Sciences in?

Synexa Life Sciences's product category is Bioanalytical Contract Research Organization (CRO). Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Key Market Segments Driving the Large Molecule Bioanalytical Technologies MarketThe large molecule bioanalytical technologies market is projected to reach $21.22 billion by 2030, growing at a compound annual growth rate of 12.2%, driven by rising monoclonal antibody pipelines, cell and gene therapy research, and increased outsourcing to contract research organizations. In October 2024, Netherlands-based Synexa Life Sciences completed the acquisition of UK-based Alderley Analytical Ltd to strengthen its large-molecule bioanalysis capabilities, including LC-MS/MS, ligand-binding assays, and immunogenicity testing services. Advanced technologies such as hospital-site sterile 3D printing are also emerging as growth drivers, exemplified by 3D Systems' FDA-cleared VSP PEEK Cranial Implant introduced in April 2024.openPR.comBiologics Testing Market Overview, Key Trends, and Insights on Major PlayersThe biologics testing market is projected to grow to $15.07 billion by 2030 with a 17.2% compound annual growth rate, driven by demand for rapid release testing, automated quality control systems, and increasing testing needs for cell and gene therapies. In October 2024, Netherlands-based Synexa Life Sciences acquired UK-based Alderley Analytical Ltd to strengthen its bioanalytical testing capabilities across mass spectrometry and ligand-binding platforms. Additionally, German biotech firm Singleron Biotechnologies GmbH launched two new instruments in June 2023 to optimize single-cell analysis workflows for cell therapy development.AlderleyanalyticalSynexa Life Sciences Acquires Alderley AnalyticalSynexa Life Sciences has acquired Alderley Analytical. This acquisition represents a strategic move to enhance Synexa's capabilities in the analytical services sector. The deal is part of Synexa's broader strategy to expand its service offerings and market presence.News-MedicalSynexa Life Sciences enrols in My Green Lab certification programSynexa Life Sciences enrolled in the My Green Lab Certification Program, aiming to reduce its environmental footprint. It will first certify its Cape Town Lab, with follow-up evaluation after 6-8 months, and plans to expand to company-wide certification.SynexagroupA Brief Introduction To Novel Modalities • Synexa Life SciencesThe article provides an overview of novel drug modalities, including antibodies, RNA therapeutics, and CAR-T therapy, highlighting their role in treating complex diseases like cancer. It notes that these innovative treatments have advanced through clinical development to gain regulatory approval and offer new therapeutic potential. Synexa Life Sciences is presented as a provider of custom assay solutions for analyzing these emerging therapies.News-MedicalClinically relevant biomarker strategies in drug developmentSynexa Life Sciences' Dr. Justin Devine and Dr. Nicholas Woudberg discuss biomarker strategies in drug development, covering the growth from 760 to 27,500 publications and the rise of immune-related biomarkers. They highlight Pfizer's 5Rs framework and AI's potential, noting bias in AI algorithms and the need for diverse datasets.SynexagroupSynexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities • Synexa Life SciencesSynexa Life Sciences has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland, to expand its biomarker and bioanalysis capabilities. This acquisition is part of Synexa's 'buy and build' strategy to become a global leader in specialist services, combining Syrinx's PK/immunogenicity expertise with Synexa's broad assay portfolio. The deal adds GLP, GCP, and GMP accredited facilities to Synexa's existing global network.GlobeNewswireInotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and BiomarkersInotiv and Synexa announced a letter of intent to form a collaboration to establish a center of excellence for biotherapeutics and biomarkers. Synexa will lease laboratory space at Inotiv's Rockville, MD site to support U.S. operations. The partnership aims to enhance scale, broaden customer base, and create cross-selling opportunities.